By bizzy.fain@gmail.com on Wed, 10/07/2020 - 14:50 Email EarlyAccess@leaptx.com ClinicalTrials.gov URL https://clinicaltrials.gov/ct2/results?lead=Leap+Therapeutics&Search=Apply&recrs=b&recrs=a&recrs=d&age_v=&gndr=&type=&rslt= Acknowledgement 5 business days EA Page https://www.leaptx.com/for-patients Sponsor Leap Therapeutics, Inc. EA Policies for Disease / Category https://www.leaptx.com/for-patients Expanded Access Listings Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors Conditions Esophageal Neoplasm Adenocarcinoma of the Gastroesophageal Junction GastroEsophageal Cancer Squamous Cell Carcinoma Gastric Adenocarcinoma Endometrial Cancer Uterine Cancer Ovarian Cancer Carcinosarcoma Gastric Cancer An Expanded Access Protocol for use of DKN-01 for the treatment of advanced solid tumors.
